The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
Open accessAbstract
Two recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomycin for curing Clostridium difficile infection (CDI) and superior for reducing CDI recurrences. In both studies, adults with active CDI were randomized to receive blinded fidaxomicin 200 mg twice daily or vancomycin 125 mg 4 times a day for 10 days. Post hoc exploratory intent-to-treat (ITT) time-to-event analyses were undertaken on the combined study 003 and 004 data, using fixed-effects meta-analysis and Cox regression models. ITT analysis of the combined 003/004 data for 1164 patients showed that fidaxomicin reduced persistent diarrhea, recurrence, or death by 40% (95% confidence interval [CI], 26%-51%; P < .0001) compared with vancomycin through day 40. A 37% (95% CI, 2%-60%; P = .037) reduction in persistent diarrhea or death was evident through day 12 (heterogeneity P = .50 vs 13-40 days), driven by 7 (1.2%) fidaxomicin versus 17 (2.9%) vancomycin deaths at <12 days. Low albumin level, low eosinophil count, and CDI treatment preenrollment were risk factors for persistent diarrhea or death at 12 days, and CDI in the previous 3 months was a risk factor for recurrence (all P < .01). Fidaxomicin has the potential to substantially improve outcomes from CDI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Self-citationFidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Self-citationZar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Teasley, D., Olson, M., Gebhard, R., Gerding, D., Peterson, L., Schwartz, M., & Lee, J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91036-x · Cited by 785
Cornely, O. A., Crook, D. W., Esposito, R., Poirier, A., Somero, M. S., Weiss, K., Sears, P., & Gorbach, S. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70374-7 · Cited by 761
Self-citationBreaking The Cycle: Treatment Strategies for 163 Cases of Recurrent Clostridium Difficile Disease
McFarland, L. V., Elmer, G. W., & Surawicz, C. M. (2002) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05839.x · Cited by 724
Muto, C. A., Pokrywka, M., Shutt, K., Mendelsohn, A. B., Nouri, K., Posey, K., Roberts, T., Croyle, K., Krystoflak, S., Patel-Brown, S., et al. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502539 · Cited by 619
Increasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, Canada
Pepin, J., Alary, M.-E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., Godin, D., & Bourassa, C. (2005) · Clinical Infectious Diseases · doi:10.1086/430315 · Cited by 570
Wenisch, C., Parschalk, B., Hasenhundl, M., Hirschl, A. M., & Graninger, W. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.5.813 · Cited by 505
Relatively Poor Outcome after Treatment of Clostridium difficile Colitis with Metronidazole
Musher, D. M., Aslam, S., Logan, N., Nallacheru, S., Bhaila, I., Borchert, F., & Hamill, R. J. (2005) · Clinical Infectious Diseases · doi:10.1086/430311 · Cited by 504
Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes
Johnson, S. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.03.010 · Cited by 397
Miller, M., Gravel, D., Mulvey, M., Taylor, G., Boyd, D., Simor, A., Gardam, M., McGeer, A., Hutchinson, J., Moore, D., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649213 · Cited by 278
Self-citationMuto, C. A., Blank, M. K., Marsh, J. W., Vergis, E. N., O'Leary, M. M., Shutt, K. A., Pasculle, A. W., Pokrywka, M., Garcia, J. G., Posey, K., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/522654 · Cited by 241
Hecht, D. W., Galang, M. A., Sambol, S. P., Osmolski, J. R., Johnson, S., & Gerding, D. N. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01623-06 · Cited by 228
Tannock, G. W., Munro, K., Taylor, C., Lawley, B., Young, W., Byrne, B., Emery, J., & Louie, T. (2010) · Microbiology · doi:10.1099/mic.0.042010-0 · Cited by 217
Self-citationClinical Risk Factors for Severe Clostridium difficile–associated Disease
Henrich, T. J., Krakower, D., Bitton, A., & Yokoe, D. S. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1503.080312 · Cited by 215
Louie, T. J., Emery, J., Krulicki, W., Byrne, B., & Mah, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01443-07 · Cited by 190
Self-citationIn Vitro Activities of OPT-80 and Comparator Drugs against Intestinal Bacteria
Finegold, S. M., Molitoris, D. R., Väisänen, M., Song, Y., Liu, C., & Bolaňos, M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4898-4902.2004 · Cited by 122
In Vitro Activity of OPT-80 against Clostridium difficile
Ackermann, G., Löffler, B., Adler, D., & Rodloff, A. C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2280-2282.2004 · Cited by 110
Credito, K. L., & Appelbaum, P. C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4430-4434.2004 · Cited by 97
Karlowsky, J. A., Laing, N. M., & Zhanel, G. G. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00476-08 · Cited by 62
Designing and interpreting HIV noninferiority trials in naive and experienced patients
Hill, A. M., & Sabin, C. A. (2008) · AIDS · doi:10.1097/qad.0b013e3282f5556d · Cited by 46
The Problem of Subgroup Analyses: An Example from a Trial on Ruptured Intracranial Aneurysms
Naggara, O. N., Raymond, J., Guilbert, F., & Altman, D. G. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2442 · Cited by 42
Wittkop, L., Smith, C. J., Fox, Z. V., Sabin, C. A., Richert, L. E., Aboulker, J.-P., Phillips, A. N., Chêne, G., Babiker, A. G., Thiébaut, R., et al. (2010) · Clinical Trials · doi:10.1177/1740774509356117 · Cited by 42
Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection
Phillips, A. N., & Walker, A. S. (2004) · AIDS · doi:10.1097/00002030-200402200-00001 · Cited by 22
Self-citation
Cited by
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Debast, S. B., Bauer, M. P., & Kuijper, E. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12418 · Cited by 1,215
van Prehn, J., Reigadas, E., Vogelzang, E. H., Bouza, E., Hristea, A., Guery, B., Krutova, M., Norén, T., Allerberger, F., Coia, J. E., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.038 · Cited by 640
Youngster, I., Russell, G. H., Pindar, C., Ziv-Baran, T., Sauk, J., & Hohmann, E. L. (2014) · JAMA · doi:10.1001/jama.2014.13875 · Cited by 629
ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections
Kelly, C. R., Fischer, M., Allegretti, J. R., LaPlante, K., Stewart, D. B., Limketkai, B. N., & Stollman, N. H. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001278 · Cited by 579
Metadata
- Authors
- Crook, D. W., Walker, A. S., Kean, Y., Weiss, K., Cornely, O. A., Miller, M. A., Esposito, R., Louie, T. J., Stoesser, N. E., Young, B. C., Angus, B. J., Gorbach, S. L., & Peto, T. E. A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-08-01
- Volume
- 55
- Issue
- suppl_2
- Pages
- S93-S103
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2149642295
- Cited by
- 260
- References
- 26
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.